Prognostic Modeling and Prevention of Diabetes Using Machine Learning Technique.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
24 09 2019
24 09 2019
Historique:
received:
25
02
2019
accepted:
20
08
2019
entrez:
26
9
2019
pubmed:
26
9
2019
medline:
28
10
2020
Statut:
epublish
Résumé
Stratifying individuals at risk for developing diabetes could enable targeted delivery of interventional programs to those at highest risk, while avoiding the effort and costs of prevention and treatment in those at low risk. The objective of this study was to explore the potential role of a Hidden Markov Model (HMM), a machine learning technique, in validating the performance of the Framingham Diabetes Risk Scoring Model (FDRSM), a well-respected prognostic model. Can HMM predict 8-year risk of developing diabetes in an individual effectively? To our knowledge, no study has attempted use of HMM to validate the performance of FDRSM. We used Electronic Medical Record (EMR) data, of 172,168 primary care patients to derive the 8-year risk of developing diabetes in an individual using HMM. The Area Under Receiver Operating Characteristic Curve (AROC) in our study sample of 911 individuals for whom all risk factors and follow up data were available is 86.9% compared to AROCs of 78.6% and 85% reported in a previously conducted validation study of FDRSM in the same Canadian population and the Framingham study respectively. These results demonstrate that the discrimination capability of our proposed HMM is superior to the validation study conducted using the FDRSM in a Canadian population and in the Framingham population. We conclude that HMM is capable of identifying patients at increased risk of developing diabetes within the next 8-years.
Identifiants
pubmed: 31551457
doi: 10.1038/s41598-019-49563-6
pii: 10.1038/s41598-019-49563-6
pmc: PMC6760163
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13805Références
Arch Intern Med. 2007 May 28;167(10):1068-74
pubmed: 17533210
Am Health Drug Benefits. 2009 Sep;2(6):218-22
pubmed: 25126292
Nephrol Dial Transplant. 2017 May 1;32(5):752-755
pubmed: 28499028
Diabetes Res Clin Pract. 2016 Jul;117:48-54
pubmed: 27329022
BMJ. 2007 Feb 10;334(7588):299
pubmed: 17237299
PLoS One. 2012;7(3):e33437
pubmed: 22442692
Psychosom Med. 2004 May-Jun;66(3):411-21
pubmed: 15184705
J Am Board Fam Med. 2009 Jul-Aug;22(4):412-22
pubmed: 19587256
BMJ. 2008 May 24;336(7654):1180-5
pubmed: 18426840
Diabetes Res Clin Pract. 2014 Jun;104(3):459-66
pubmed: 24742930
Front Genet. 2018 Nov 06;9:515
pubmed: 30459809
Diabetologia. 2013 Mar;56(3):457-66
pubmed: 23232641
Eur J Epidemiol. 2015 Jan;30(1):35-45
pubmed: 25421785
Epidemiol Rev. 2011;33:46-62
pubmed: 21622851
Int J Med Sci. 2014 Sep 06;11(11):1185-200
pubmed: 25249787
IEEE/ACM Trans Comput Biol Bioinform. 2017 May-Jun;14(3):687-695
pubmed: 26890920
J Am Coll Cardiol. 2015 Mar 3;65(8):846-855
pubmed: 25601032
J Biomed Inform. 2013 Apr;46(2):266-74
pubmed: 23200810
J Clin Epidemiol. 2018 Jun;98:133-143
pubmed: 29174118
Phys Ther. 2008 Nov;88(11):1254-64
pubmed: 18801858
Diabetes Care. 2006 Aug;29(8):1872-7
pubmed: 16873795
Sci Rep. 2018 Feb 1;8(1):2112
pubmed: 29391513
Horm Metab Res. 2009 Feb;41(2):86-97
pubmed: 19021089
Lancet. 2008 May 24;371(9626):1783-9
pubmed: 18502303
Can J Diabetes. 2015 Apr;39(2):152-6
pubmed: 25577729
Diabetes Care. 2018 May;41(5):917-928
pubmed: 29567642
Front Endocrinol (Lausanne). 2017 Dec 05;8:343
pubmed: 29259578
Diabetes Care. 1999 May;22(5):756-61
pubmed: 10332677